Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. | Available online http content 11 2 R52 Research article Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis observational study from the British Society of Rheumatology Biologics Register Amr A Saad1 Darren M Ashcroft1 Kath D Watson2 Kimme L Hyrich2 Peter R Noyce1 Deborah PM Symmons2 for the British Society for Rheumatology Biologics Register School of Pharmacy and Pharmaceutical Sciences University of Manchester Oxford Road Manchester M13 9PT UK 2Arthritis Research Campaign Epidemiology Unit University of Manchester Oxford Road Manchester M13 9PT UK Corresponding author Darren M Ashcroft Received 29 Dec 2008 Revisions requested 9 Feb 2009 Revisions received 7 Mar 2009 Accepted 8 Apr 2009 Published 8 Apr 2009 Arthritis Research Therapy 2009 11 R52 doi ar2670 This article is online at http content 11 2 R52 2009 Bagshaw et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract Introduction Anti-TNF therapies represent a breakthrough in the treatment of severe psoriatic arthritis. However little is known about long-term drug persistence with these treatments in patients with psoriatic arthritis in routine clinical practice. The aim of this study was to assess persistence with first-course and second-course treatment with anti-TNF agents in a prospective cohort of psoriatic arthritis patients and to identify factors associated with and reasons for drug discontinuation. Methods A total of 566 patients with psoriatic arthritis were registered with the British Society for Rheumatology Biologics Register first anti-TNF agent etanercept n 316 infliximab n 162 and adalimumab n 88 . Treating
